Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
Fiche publication
Date publication
juin 2017
Journal
Lancet (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric
Tous les auteurs :
Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, Faucheron JL, Jafari M, Portier G, Meunier B, Sileznieff I, Prudhomme M, Marchal F, Pocard M, Pezet D, Rullier A, Vendrely V, Denost Q, Asselineau J, Doussau A
Lien Pubmed
Résumé
Organ preservation is a concept proposed for patients with rectal cancer after a good clinical response to neoadjuvant chemotherapy, to potentially avoid morbidity and side-effects of rectal excision. The objective of this study was to compare local excision and total mesorectal excision in patients with a good response after chemoradiotherapy for lower rectal cancer.
Mots clés
Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Adjuvant, methods, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoadjuvant Therapy, methods, Neoplasm Staging, Organ Preservation, methods, Postoperative Complications, prevention & control, Prospective Studies, Rectal Neoplasms, pathology, Recurrence, Treatment Outcome
Référence
Lancet. 2017 Jun;: